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Abstract
The advent of CRISPR/Cas9 has made genome editing possible in virtually any organism, 
including those not previously amenable to genetic manipulations. Here, we present an 
optimization of CRISPR/Cas9 for application to early avian embryos with improved efficiency via 
a three-fold strategy. First, we employed Cas9 protein flanked with two nuclear localization signal 
sequences for improved nuclear localization. Second, we used a modified guide RNA (gRNA) 
scaffold that obviates premature termination of transcription and unstable Cas9-gRNA 
interactions. Third, we used a chick-specific U6 promoter that yields 4-fold higher gRNA 
expression than the previously utilized human U6. For rapid screening of gRNAs for in vivo 
applications, we also generated a chicken fibroblast cell line that constitutively expresses Cas9. As 
proof of principle, we performed electroporation-based loss-of-function studies in the early chick 
embryo to knock out Pax7 and Sox10, key transcription factors with known functions in neural 
crest development. The results show that CRISPR/Cas9-mediated deletion causes loss of their 
respective proteins and transcripts, as well as predicted downstream targets. Taken together, the 
results reveal the utility of this optimized CRISPR/Cas9 method for targeted gene knockout in 
chicken embryos in a manner that is reproducible, robust and specific.
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Introduction
Chick embryos have long been used as a model organism to address important questions in 
developmental biology due to their accessibility to transplantation, surgical ablations, and 
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other genetic perturbations. This has allowed researchers to regulate gene expression in a 
spatiotemporally controlled manner at diverse stages of development (Darnell and 
Schoenwolf, 2000; Streit et al., 2013). Traditionally, loss-of-function experiments have 
utilized anti-sense morpholinos (Corey and Abrams, 2001), dominant-negative constructs or 
shRNAs (Sauka-Spengler and Barembaum, 2008). However, these techniques are transient, 
becoming diluted by cell proliferation during development, and there have been increasing 
concerns regarding possible lack of specificity due to either off-target effects or reagent 
toxicity (Eisen and Smith, 2008; Gerety and Wilkinson, 2011; Kok et al., 2015; Schulte-
Merker and Stainier, 2014).
One alternative to these approaches is CRISPR/Cas9 (Clustered Regularly Interspaced Short 
Palindromic Repeats/CRISPR-Associated protein 9), a revolutionary technology that has 
enabled efficient knockout of target genes across a wide range of model organisms (Cong et 
al., 2013; Dickinson et al., 2013; Gagnon et al., 2014; Ren et al., 2014; Stolfi et al., 2014). 
CRISPR/Cas9 involves the formation of a complex between guide RNA (gRNA) and Cas9, 
an endonuclease enzyme derived from Streptococcus pyogenes, which then binds to specific 
targets in the genome. Once bound to genomic DNA, this complex introduces double-
stranded breaks that are imperfectly repaired by Non-Homologous End Joining repair 
enzymes, often leading to a frame-shift insertion or deletion, and subsequent truncation 
and/or degradation of the target transcript (Jinek et al., 2012; Qi et al., 2013; Sternberg et al., 
2014). Specificity is achieved through Watson-Crick base pairing between the protospacer 
domain of the gRNA and the target locus in the genome, together with recognition of a 
Protospacer Adjacent Motif (PAM) by Cas9. Not only does CRISPR/Cas9 offer high 
spatiotemporal specificity (Stolfi et al., 2014), but it also enables investigation of the roles of 
non-coding genetic elements such as enhancers and insulators in regulating gene expression 
during development (Diao et al., 2016; Han et al., 2014; Korkmaz et al., 2016; Lopes et al., 
2016; Thakore et al., 2015).
In spite of all its advantages, the CRISPR/Cas9 system has not been fully optimized for 
application in chick embryos. Early attempts at implementation in avian embryos employed 
a tetracycline-inducible Cas9 system to perform gene editing of Pax7 using Tol-2 mediated 
integration at stages after neural tube closure (Véron et al., 2015). While useful, this 
approach functioned at low efficiency, particularly at early developmental stages (Bai et al., 
2016; Oishi et al., 2016; Véron et al., 2015). Since then, several studies performed in other 
model systems have reported optimizations of individual CRISPR/Cas9 components, 
improving our understanding of this gene-editing technology (Chen et al., 2013; Doench et 
al., 2016; Gandhi et al., 2017; Port et al., 2014; Ren et al., 2014).
To extend the usefulness of this technique to the early chick embryo, we have adapted an 
optimized CRISPR/Cas9 system for efficient genome editing by implementing three 
modifications. First, we used a previously characterized Cas9 protein flanked with two 
nuclear localization sequences (NLS) for enhanced compartmentalization in the nucleus 
(Chen et al., 2013; Stolfi et al., 2014). Second, we used a modified gRNA “F+E” scaffold 
that has been shown to resolve issues including premature termination of RNA Polymerase-
III-mediated transcription of the gRNA cassette and unstable interaction between Cas9 
protein and transcribed gRNA (Chen et al., 2013; Orioli et al., 2011). Third, we improved 
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gRNA expression by using a chick-specific U6 promoter that outperforms a human U6 
promoter in chick embryos (Cong et al., 2013; Kudo and Sutou, 2005; Wise et al., 2007).
In the present study, we demonstrate the efficiency of this improved CRISPR/Cas9 system 
by performing functional testing in the avian neural crest. The neural crest is a multipotent 
cell population that originates at the neural plate border, then migrates extensively 
throughout the embryo to give rise to numerous cell types (Le Douarin and Kalcheim, 1982; 
Green et al., 2015; Simões-Costa and Bronner, 2015). We test the ability of our optimized 
CRISPR/Cas9 system to knock out key transcription factors in the neural crest, including the 
neural plate border specifier Pax7 (Basch et al., 2006), and the neural crest specifier, Sox10 
(Betancur et al., 2010; Carney et al., 2006), among others. The results show that our 
CRISPR/Cas9 system is robust and reproducible as a means for knocking out genes of 
interest in chicken embryos.
Results and Discussion
Here, we present a strategy using optimized CRISPR/Cas9 components to enable efficient 
knockouts at early developmental stages, starting with the transcription factor Pax7 and 
extending our approach to other genes of known importance in chick neural crest 
development.
Optimizing CRISPR/Cas9 components for application in chick embryos
As a first step, we cloned a previously published human codon-optimized spCas9 (Qi et al., 
2013) flanked with an NLS sequence on both the N and C-terminus under the regulation of 
the chicken beta-actin promoter (CAGG) (Alexopoulou et al., 2008) to ensure optimal 
nuclear localization of Cas9 protein in vivo (Figure 1A). It was previously shown that two 
NLS sequences are necessary for proper nuclear localization of Cas9 protein (Chen et al., 
2013). Co-electroporation of Cas9 (CAGG>nls-Cas9-nls) with CAGG>H2B-RFP and a 
control gRNA (U6.3>Control.gRNA.f+e), followed by immunostaining for Cas9 protein 
demonstrated effective nuclear localization in transfected cells (Figure 1B–D). Second, we 
cloned all protospacer sequences targeting genes of interest in a previously modified gRNA 
‘F+E’ scaffold (Figure 1E) that contains a ‘flipped’ (F) Adenine-Uracil pair downstream of 
the protospacer domain and an ‘extended’ (E) Cas9 stem handle (Chen et al., 2013). These 
modifications were shown to improve RNA polymerase III-mediated gRNA transcription by 
minimizing the possibility of premature termination of transcription, as well as stabilize the 
interaction between Cas9 protein and the transcribed gRNA, respectively (Chen et al., 2013; 
Stolfi et al., 2014). Third, we tested different RNA Polymerase III-mediated promoters for 
their ability to drive gRNA expression in transfected cells in vivo. Although most CRISPR 
knockout experiments performed in mammalian systems have used a human U6 promoter to 
govern gRNA expression (Jinek et al., 2013; Mali et al., 2013; Wang et al., 2014), species-
specific U6 promoters have been used in non-mammalian model organisms such as 
zebrafish, Ciona, and Drosophila (Ablain et al., 2015; Nishiyama and Fujiwara, 2008; Port et 
al., 2014). To that effect, we directly compared gRNA expression levels mediated by the 
standard human U6 (hU6) promoter with a chicken U6 (cU6.3) promoter.
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To this end, we electroporated the right side of gastrulating chick embryos at Hamburger 
Hamilton stage 4 (HH4) (V. Hamburger, 1951) with different U6-variant>bCat.gRNA.f
+e.NoTermGFP constructs (Figure 1F; see Materials and Methods for details), and allowed 
embryos to develop until stage HH9-10. A reporter (CAGG>H2B-RFP) was co-
electroporated to normalize electroporation variability between embryos. Using in situ 
hybridization against GFP, we observed increased gRNA transcription with the chicken U6.3 
promoter variant compared with the hU6 promoter (Figure 1G–H). After isolating RNA and 
reverse-transcribing cDNA from three biological replicates electroporated with the two 
variants, we performed quantitative RT-PCR (qRT-PCR) using primers specific to GFP. The 
results confirmed our in situ hybridization analysis, showing that the chicken-specific U6.3 
promoter resulted in a 4-fold increase in gRNA transcription compared to a human U6 
promoter used in previous studies (Figure 1I). The chicken U6.3 promoter variant also 
outperformed an additional chick U6 promoter (data not shown), demonstrating that intra-
species variability should be considered when selecting promoters to drive expression of 
small RNA molecules. Taken together, our results identify chicken-specific U6.3 promoter 
as an improvement over previously used human U6 promoters for gRNA transcription, and 
highlight the importance of U6 promoter selection for subsequent loss-of-function studies.
In addition to improving the U6 promoter for delivery of gRNA, we incorporated a 
screening step into our gRNA design strategy to help eliminate the possibility of off-target 
effects. Multiple groups have previously highlighted design principles that correlate directly 
with the activity of the gRNA in vivo (Cho et al., 2014; Gandhi et al., 2017; Tsai et al., 
2015). To simplify our gRNA design, we considered these principles and employed the MIT 
CRISPR program (http://crispr.mit.edu) for initial target site selection. When presented with 
multiple protospacer sequences, those with high scoring alignments outside the desired locus 
were discarded. As such, all gRNAs used for functional analysis in this study were designed 
to avoid off-target gRNA sites, thereby minimizing non-specific effects.
CRISPR/Cas9-mediated knockout of key neural crest genes
To establish proof of principle, we first used our optimized CRISPR system to target the 
transcription factor Pax7 in chick embryos. Pax7 is one of the earliest markers of the neural 
plate border, and its loss using a translation-blocking morpholino results in a significant 
decrease in neural crest markers such as Snai2, Sox9, and FoxD3 (Basch et al., 2006; 
Labosky and Kaestner, 1998; Simões-Costa and Bronner, 2015; Simões-Costa et al., 2012). 
We designed a gRNA targeting the splice acceptor site of the second exon of Pax7 (Figure 
2A) and expressed it under the regulation of the optimized chicken U6.3 promoter 
(U6.3>Pax7.1.gRNAf+e). To confirm CRISPR-mediated genomic editing at the desired 
locus, we co-electroporated U6.3>Pax7.1.gRNAf+e along with CAGG>nls-Cas9-nls and 
CAGG>H2B-RFP bilaterally, and harvested embryos at stage HH10. Embryos were 
dissociated to isolate RFP+ cells by flow cytometry, which were then used to prepare 
genomic DNA for genotyping. The target locus was PCR-amplified and sequenced to 
identify CRISPR-induced mutations. As expected, a range of different insertion (red) and 
deletion (gray) mutations were identified in the gRNA target sequence (Figure 2B), 
demonstrating that the Cas9 protein used in this study can induce targeted genomic 
mutations. We next co-electroporated the Pax7-targeting gRNA (U6.3>Pax7.1.gRNAf+e) 
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along with CAGG>nls-Cas9-nls and CAGG>H2B-RFP on the right side of gastrulating 
stage HH4 embryos, and then cultured these until developmental stage HH9+ (Figure 2C). 
The left side was electroporated with a control gRNA that has no recognition sites in the 
chick genome (U6.3>Control.gRNAf+e) and served as an internal control. Immunostaining 
using a Pax7 antibody revealed downregulation of Pax7 protein level on the side 
electroporated with Pax7.1 gRNA compared to the control side (Figure 2D), consistent with 
the anticipated splicing errors and/or frame shifts following Cas9-induced mutations. When 
overlaying RFP and Pax7 channels, we observed that all cells that were successfully 
transfected with the H2B-RFP plasmid showed no detectable Pax7 protein compared to the 
control side, where transfected neural crest cells were double-positive for RFP and Pax7 
(Figure 2E, E′, E″). This was particularly interesting because Pax7 is expressed in the 
neural plate border as early as stage HH4+ (Basch et al., 2006; Roellig et al., 2017). Given 
that several hours after electroporation are required for the production of Cas9 protein after 
electroporation (Stolfi et al., 2014), this suggests that the half-life of Pax7 protein is short 
enough for our CRISPR/Cas9 system to cause loss of Pax7 protein expression within 14 
hours. To confirm that loss of Pax7 would manifest itself in a loss of neural crest migration 
phenotype, we co-immunostained stage HH10 embryos for HNK1, a surface antigen that has 
traditionally been used as a marker for migratory neural crest cells (Basch et al., 2006). As 
expected, we saw a strong loss of HNK1 expression on the Pax7 knock out side of the 
embryo compared to the control side (Figure 2F), suggesting that loss of Pax7 protein 
resulted in the failure of neural crest specification and ultimately, migration. In other 
embryos, we co-electroporated CAGG>nls-Cas9-nls and U6.3>Pax7.1.gRNAf+e unilaterally 
on the right side at stage HH4, and allowed the embryos to develop until stage HH9. 
Transverse sections through a representative embryo revealed an almost complete loss of 
Pax7 expression in the dorsal neural tube (Figure 2G–2G″). Looking closer at this region, 
we saw that the number of cells, as assessed by 4,6–diamidino-2-phenylindole (DAPI) 
staining, appeared unchanged (Figure 2G‴). This suggests that the loss in Pax7 expression 
was a result of CRISPR/Cas9-mediated modification of the Pax7 locus, and that the 
concentration of plasmids electroporated in the embryo did not result in cellular toxicity.
Once we verified efficient reduction in protein levels, we asked whether this effect reflects 
the presence of fewer transcripts of target genes following CRISPR/Cas9-mediated 
mutations. To test this, we designed a gRNA targeting the start codon of Sox10 (Figure 3A), 
a transcription factor expressed in the migrating neural crest (Figure 3C) that plays a critical 
role in the migratory neural crest gene regulatory network (Betancur et al., 2010; Carney et 
al., 2006; Ghislain et al., 2003). We began by co-electroporating CAGG>nls-Cas9-nls, 
U6.3>Sox10.1.gRNAf+e, and CAGG>H2B-RFP bilaterally in stage HH4 embryos, and 
genotyping RFP+ cells sorted by flow cytometry as described above for the Pax7 locus. 
Similar to Pax7, we identified several mutations surrounding the Sox10 target sequence 
(Figure 3B). We co-electroporated CAGG>nls-Cas9-nls, U6.3>Sox10.1.gRNAf+e, and a 
reporter CAGG>H2B-RFP on the right side of a stage HH4 embryo. The left side was 
electroporated with U6.3>Control.gRNAf+e and served as an internal control. Embryos 
were cultured ex ovo until stage HH9-10, then processed for in situ hybridization. The 
results reveal a substantial decrease in Sox10 transcript levels on the side electroporated with 
the Sox10.1 gRNA (Figure 3D, E), both in the neural crest and in the otic placode (Figure 
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3E′) (Betancur et al., 2011). The loss of transcripts detected by in situ hybridization is 
consistent with the degradation of mutant transcripts by nonsense-mediated decay (Losson 
and Lacroute, 1979). To confirm that the effect on Sox10 transcripts is reflected at the Sox10 
protein level, we immunostained for Sox10 protein in embryos electroporated using the 
same strategy. We observed a nearly complete loss of Sox10 in the right side of the embryo 
following Sox10.1 gRNA electroporation (Figure 3F, F′). Similarly, knock-out of Pax7 
caused a near complete loss of Pax7 transcripts (Figure 4A). Taken together, these results 
show that our CRISPR/Cas9 system is highly robust at causing loss of function of target 
genes.
To extend this system to other genes implicated in neural and neural crest development, we 
designed gRNAs against Sox2 and performed electroporations similar to those described 
above. The result demonstrates efficient loss of Sox2 protein on the electroporated side of 
the same embryo compared to the control side (Supplemental Figure 1).
Establishing epistatic relationships using CRISPR/Cas9
The ability to knock out genes of interest is particularly important when constructing gene 
regulatory networks underlying developmental events. To demonstrate that CRISPR/Cas9 
can be used to interrogate regulatory relationships between genes, we examined the effects 
of knocking out Pax7 and Sox10 on other neural crest transcription factors. To this end, we 
co-electroporated CAGG>nls-Cas9-nls, CAGG>H2B-RFP, and control 
U6.3>Control.gRNAf+e on the left side with Pax7-targeting U6.3>Pax7.1.gRNAf+e or 
Sox10-targeting U6.3>Sox10.1.gRNAf+e on the right side of gastrulating stage HH4 
embryos. The embryos were cultured ex ovo until stage HH9-10 and then processed for in 
situ hybridization for Pax7, FoxD3, Ets1, and Sox10 (Figure 4A). Pax7 knockout resulted in 
reduced staining for Pax7, FoxD3, Ets1 and Sox10 transcripts in the migratory neural crest 
(Figure 4B–E). On the other hand, knock-out of Sox10 caused a loss of its own expression, 
but as expected had no effect on Pax7, FoxD3 or Ets1 (Figure 4F–I), all of which are 
expressed prior to Sox10 and upstream in the neural crest GRN. Thus, these results 
recapitulate previously demonstrated gene regulatory interactions (Simões-Costa and 
Bronner, 2015) and confirm that Pax7 acts as an upstream regulator of FoxD3, Ets1 and 
Sox10 whereas Sox10 expression is downstream of these transcription factors and its 
subsequent loss does not affect expression of its upstream regulators.
To further test the ability of CRISPR/Cas9 to decipher direct gene regulatory interactions, 
we examined the effects of Pax7 loss on one of its direct transcriptional targets, FoxD3. We 
have previously shown that Pax7 directly regulates activity of FoxD3 at cranial levels by 
binding to the NC1 enhancer element upstream of the FoxD3 coding sequence (Simões-
Costa et al., 2012) (Figure 5A). To confirm this epistatic relationship, we asked if knocking 
out Pax7 using CRISPR/Cas9 would reduce exogenous FoxD3 NC1 enhancer activity. To 
this end, we co-electroporated CAGG>nls-Cas9-nls, U6.3>Pax7.1.gRNAf+e, and FoxD3-
NC1.1>eGFP reporter construct containing a constitutively active version of the FoxD3-NC1 
enhancer on the right side of stage HH4 embryos (Figure 5B). The left internal control side 
was co-electroporated with CAGG>nls-Cas9-nls, FoxD3-NC1.1>eGFP, and 
U6.3>Control.gRNAf+e. After electroporation, embryos were cultured ex ovo until stage 
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HH9-9+. Consistent with the observed Pax7 knockout detected by immunostaining (Figure 
5C), the level of eGFP expression was reduced on the side of the embryo that was 
electroporated with Pax7.1 gRNA compared to the control side (Figure 5D), validating the 
requirement of Pax7 for the activation of the FoxD3-NC1 enhancer. While the exogenous 
reporter activity through the NC1 enhancer was effectively lost, we further hypothesized that 
the absence of a transcriptional input from Pax7 would result in reduced endogenous FoxD3 
protein levels. To test this, we electroporated stage HH4 embryos with U6.3>Pax7.1.gRNAf
+e and U6.3>Control.gRNAf+e on the right and left side respectively, along with 
CAGG>nls-Cas9-nls and CAGG>H2B-RFP on both sides, cultures embryos till stage 
HH9+, and collected cell lysates for immunoblotting. Consistent with our hypothesis, both 
Pax7 and FoxD3 protein levels were significantly reduced on the side electroporated with 
the Pax7-targeting gRNA (Figure 5E). Quantification of these data revealed a 4-fold and 15-
fold decrease in the levels of Pax7 and FoxD3 protein, respectively (Figure 5F, G) on the 
side electroporated with the Pax7-targeting gRNA compared to the control side. Taken 
together, these results demonstrate the applicability of our optimized CRISPR/Cas9 system 
for investigating direct epistatic relationships among different genes.
The ‘gold standard’ control for demonstrating specificity in loss-of-function experiments is 
to perform a rescue that recovers function when the lost protein is exogenously supplied. To 
extend this to our CRISPR/Cas9 system, we asked if we could restore FoxD3-NC1.1 
enhancer activity after Pax7 knockout by over-expressing Pax7 exogenously. To this end, we 
electroporated the coding sequence of Pax7 under the control of a basal promoter 
(CAGG>Pax7CDS-IRES-H2B-RFP (Roellig et al., 2017)) (Figure 5H) along with 
CAGG>nls-Cas9-nls, U6.3>Pax7.1.gRNAf+e, and FoxD3-NC1.1>eGFP on the right side of 
stage HH4 embryos (Figure 5I). The left side was electroporated with U6.3>Control.gRNAf
+e and served as an internal control. The PAM adjacent to the Pax7.1 gRNA target site lies 
in the first intron, and hence would be missing from the Pax7 coding sequence. Since 
identification of the PAM is essential for Cas9 binding, we predicted that our Pax7 
overexpression construct would not be recognized by the Cas9-Pax7.1.gRNA complex. 
Embryos were developed until stage HH9-10, after which they were imaged for FoxD3-
NC1.1 enhancer driven eGFP reporter expression. The activity of the FoxD3-NC1.1 
enhancer appeared similar on both the control and experimental sides of the embryo (Figure 
5J), indicating that exogenous Pax7 rescued the CRISPR/Cas9-mediated loss of endogenous 
Pax7 protein, and consequently, the FoxD3-NC1.1 reporter activity, thereby demonstrating 
specificity. Taken together, these results suggest that our optimized CRISPR system is 
specific in causing functional gene knockouts at target loci in the chicken genome and 
demonstrate the functionality of this approach in ordering gene regulatory interactions.
Rapid screening of gRNAs using a Cas9-integrated chicken DF-1 fibroblast cell line
Validating individual gRNAs for knocking out genes in vivo using CRISPR/Cas9 can be 
cumbersome and as a result continues to be one of the potential limitations of designing 
CRISPR/Cas9 experiments in chick embryos. Although we have reported a simple sorting-
based protocol to quantify gRNA efficacy in vivo, we sought to develop a simpler strategy to 
overcome the need for cell sorting. To this end, we have modified the chicken DF-1 
fibroblast cell line to constitutively express Cas9 that has been integrated in the genome 
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using a Tol2-flanked CAGGS-driven Cas9-2A-PuroR cassette and T2TP transposase (Sato et 
al., 2007) (Figure 6A). We validated the constitutive nuclear expression of Cas9 by 
immunostaining using an antibody against Cas9, followed by DAPI-counterstaining (Figure 
6B–D). Interestingly, the expression level was variable in different cells, suggesting that the 
transposase-mediated genomic integration events were distinct. Once we verified the stable 
integration of Cas9 in DF-1 cells, we used this system to assay the efficacy of gRNAs for in 
vivo application in embryos. To this end, we transfected Cas9-integrated DF-1 cells with 
gRNAs targeting the genomic loci of genes Pax7 and Sox10 using gRNAs described in 
previous sections (U6.3>Pax7.1.gRNAf+e or U6.3>Sox10.1.gRNAf+e). As a control for 
transfection and to calculate the transfection rate, we also transfected a different well of cells 
with CAGG>H2B-RFP. After 48 hours of incubation, we isolated genomic DNA from the 
Pax7 and Sox10-targeted cells for genotyping. As expected, both gRNAs generated 
mutations around the gRNA targeting site for the two genes (Figure 6E–F) that would have 
resulted otherwise in a splicing error and/or frameshift in the coding sequence. Importantly, 
the efficacy rates for the two gRNAs from unsorted DF-1 cells were consistent with the 
results obtained from sorted chick embryo cells (Figure 2B, 3B). Taken together, these 
results demonstrate the utility of our Cas9-DF1 cell line in simplifying the experimental 
designs for future CRISPR/Cas9 knockout experiments in chick embryos.
Conclusion
In summary, here we demonstrate the application of the CRIPSR/Cas9 system for effective 
somatic cell genome editing in chicken embryos. The chick embryo offers many advantages 
for analysis of gene function in amniotes in vivo because of its accessibility, ease of 
manipulation, and low cost. Moreover, the ability to perform bilateral electroporations 
enables an internal control within a single embryo. In the past, loss-of-function studies have 
relied upon morpholinos, dominant negatives, or RNAi approaches, all of which are 
transient, and thus useful for relatively short-term analysis. Although morpholinos offer a 
rapid and efficient method to block translation or splicing, concerns regarding the possibility 
of toxicity and off-target effects make it important to consider alternative approaches. To this 
end, we optimized our Cas9 and gRNA expression plasmids by incorporating three 
modifications: first, by employing two NLS sequences for higher nuclear expression of Cas9 
protein (Chen et al., 2013); second, by using a modified gRNA (“F+E”) scaffold to enhance 
in vivo gRNA transcription (Chen et al., 2013; Stolfi et al., 2014); and third, by using a 
species-specific chicken U6 promoter. In addition, we have generated a Cas9-DF1 cell line 
that greatly streamlines the process of gRNA design for knockout experiments in chick 
embryos. The results highlight the robustness and reproducibility of this modified CRISPR/
Cas9 system for generating loss-of-function in chick embryos in a manner that can be 
applied to many developmental processes, including protein functional analysis and the 
dissection of gene regulatory interactions.
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Materials and Methods
Molecular cloning
The Pax7, Sox10, and Sox2 genomic loci were obtained from the UCSC genome browser 
(Karolchik et al., 2003). The initial set of gRNA targets were designed by searching these 
loci for the motif G-<N20>-GG. Protospacer sequences overlapping with splice junctions 
were preferred over ones within coding sequences. The Gallus gallus 5.0 genome assembly 
available on the UCSC genome browser was used to screen for polymorphisms. Using this 
approach, we generated the gRNA targets used in this study: Pax7 
(GGCCCAGCGGGGTGGACACT), Sox10 (GAGATCTTGGTCATCAGCCA), and Sox2 
(GCCCAGCAAACTTCGGGGGG). We also designed a control gRNA with a protospacer 
sequence not found in the chicken genome (GCACTGCTACGATCTACACC). Previously 
described design principles (Doench et al., 2014; Gandhi et al., 2017; Moreno-Mateos et al., 
2015) were followed when choosing between multiple gRNA targets for the same gene to 
avoid off-target effects. All protospacers were cloned into a modified gRNA “F+E” 
backbone, which was a gift from Lionel Christiaen (Addgene plasmid # 59986). The human 
codon-optimized Cas9 was obtained as a gift from Lionel Christiaen (Addgene plasmid # 
59987). nls-Cas9-nls was PCR amplified using High-Fidelity Phusion polymerase (NEB) 
and inserted downstream of the chicken beta-actin promoter (CAGG). Our gRNA and Cas9 
vectors can be obtained through Addgene (https://www.addgene.org/Marianne_Bronner/).
For the U6 promoter optimization assay, the “gRNA.f+e” backbone was PCR amplified to 
remove the terminator sequence from the 3′ end of the scaffold. This amplicon was fused to 
the 5′ end of GFP using overlap PCR, and this entire cassette was then cloned downstream 
of the human U6 and chicken U6.3 promoter (gift from Chao-Yuan Yeh at the Cheng-Ming 
Chuong lab).
For qRT-PCR, following electroporation with the human and chicken U6 promoter 
constructs, RNA was extracted using the RNAqueous kit (Ambion). cDNA strands were 
synthesized using SuperScript III Reverse Transcriptase (Invitrogen) using random 
hexamers, and stored at −20°C. Primers for qRT-PCR against GFP were (for 5′-
AAGCTGACCCTGAAGTTCATCTGC-3′, rev 5′-
CTTGTAGTTGCCGTCGTCCTTGAA-3′).
Electroporation
Fertilized chicken embryos were obtained from local farmers, and were electroporated at 
stage HH4 using previously described techniques (Sauka-Spengler and Barembaum, 2008). 
For Pax7 and Sox10 knockout experiments, the right side of the embryos were 
electroporated with 2μg/μL CAGG>nls-Cas9-nls, 1.5μg/μL U6.3>Pax7/Sox10gRNAf+e and 
2μg/μL CAGG>H2B-RFP, while the left side was electroporated with 1.5μg/μL 
U6.3>Control.gRNAf+e along with Cas9 and H2B-RFP reporter. For the epistasis 
experiment, 2μg/μL of FoxD3-NC1.1>eGFP was electroporated on both sides of the embryo, 
combined with CRISPR/Cas9 reagents as described above. For overexpression of Pax7, 2μg/
μL of CAGG>Pax7CDS-IRES-H2B-RFP was electroporated on the right side leaving the 
other side as control. Electroporated embryos were cultured ex ovo in 35mm dishes with 
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1mL of albumen at 37°C in humidified chambers until the desired Hamburger Hamilton 
stages were reached (V. Hamburger, 1951).
Genotyping
Whole embryos were electroporated with CAGG>nls-Cas9-nls and CAGG>H2B-RFP 
together with either U6.3>Pax7.1.gRNAf+e or U6.3>Sox10.1.gRNAf+e at stage HH4, then 
incubated to stage HH10. Live embryos were dissected in Ringer’s solution on ice, washed 
with sterile PBS, and dissociated with Accumax cell dissociation solution (EMD Millipore). 
Dissociation was terminated by addition of Hanks Buffered Saline Solution (HBSS) 
(Corning) supplemented with 25mM HEPES pH 7.0, 2.5mg/mL BSA Fraction V (Sigma), 
and 10mM MgCl2. Cells were then passed through a 40 μm filter to remove debris, and 
RFP+ cells were then isolated using a Sony Synergy 3200 cell sorter equipped with a 561nm 
laser (Caltech Flow Cytometry Facility). Cells were pelleted, then genomic DNA was 
prepared in 20 μl 1x AccuPrime PCR Buffer II (ThermoFisher). This resuspension was 
incubated at 95°C for 15 minutes, 2.5 μl 20 mg/ml Proteinase K was added and reincubated 
at 55°C for 2 hours with frequent pipetting to mix, then heated to 95°C for another 15 
minutes. This resulting preparation was used for PCR amplification using AccuPrime High 
Fidelity Taq Polymerase (ThermoFisher) with Pax7 (for 5′-
TAAATCGCGAGGCAATTTCT-3′, rev 5′-GTCCCCTCGACCCTACTTTC-3′) or Sox10 
(for 5′-GGAGATATGTGAGCAGACAGG-3′, rev 5′-TTCCATTGACCCGAACAGG-3′) 
locus primers. Amplicons were then PCR purified (QIAGEN) and TA cloned into pGEM T 
Easy (Promega) for transformation and Sanger sequencing (Laragen).
In-situ hybridization
Whole mount embryos were fixed in 4% paraformaldehyde for 2 hours at room temperature. 
Post-fixation, embryos were washed three times in PBS-0.1% Tween, and were serially 
dehydrated in methanol, after which they were stored at −20°C. In situ hybridization for 
Sox10 (Betancur et al., 2010), Pax7 (Basch et al., 2006), FoxD3 (Kos et al., 2001), and Ets1 
(Barembaum and Bronner, 2013) was performed using previously described protocol 
(Acloque et al., 2008). In situ hybridization for GFP was performed using a modified 
protocol which involved incubating the embryos in DNase I (Promega) at 37°C for 1 hour 
(Arede and Tavares, 2008). The DIG-labeled RNA probe against GFP was a gift from 
Marcos Simões-Costa.
Immunostaining and Imaging
Whole-mount immunostaining was performed using previously described procedures (Ezin 
et al., 2009). Briefly, embryos cultured ex ovo at 37°C post-electroporation were fixed in 4% 
paraformaldehyde in phosphate buffer for 20 minutes at room temperature. Embryos were 
then washed three times in PBS-0.1% Triton for 5 minutes each, after which they were 
blocked for 2 hours at room temperature in 5% donkey serum for Pax7 and Sox10 staining, 
and 5% goat serum for Pax7 and HNK1 co-staining. Embryos were incubated with primary 
antibody at 4°C for 1 night for Pax7, and 2 nights for Sox10. The concentrations of primary 
antibodies used were: Pax7 (1:10; Developmental Studies Hybridoma Bank, Iowa city, 
Iowa), Sox10 (1:250; R&D Systems Cat # AF2864), HNK1 (1:5; Developmental Studies 
Hybridoma Bank, Iowa city, Iowa), RFP (1:500; MBL Cat # PM005), GFP (1:500; Abcam 
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Cat # Ab290), Cas9 (1:500; Diagenode Cat # C15200216). The signal was detected using 
secondary antibodies Donkey anti-mouse IgG1 Alexa Fluor 488 and Goat anti-mouse IgG1 
Alexa Fluor 488 (for Pax7 and Cas9), Donkey anti-goat IgG1 Alexa Fluor 488 (for Sox10), 
Goat anti-mouse IgM Alexa Fluor 350 (for HNK1), donkey anti-rabbit IgG1 Alexa Fluor 
594 (for RFP), and donkey anti-rabbit IgG1 Alexa Fluor 488 (for GFP), respectively, all 
diluted to 1:500 final concentrations in PBS-0.5% Triton with 5% donkey or goat serum. For 
DAPI staining, transverse sections were incubated with DAPI (0.1μg/mL) for 5 minutes. 
Whole mount embryos were imaged on a Zeiss Imager M2 with an ApoTome module. 
Transverse sections were imaged on Zeiss 710 inverted confocal microscope at the Caltech 
Biological Imaging Facility. All images were processed using FIJI imaging software 
(Schindelin et al., 2012).
Cryosectioning
Whole mount embryos immunostained for Pax7 and RFP were incubated in 5% sucrose for 
2 hours at room temperature, followed by overnight incubation in 15% sucrose. The next 
day, embryos were incubated in gelatin at 37°C for 6 hours and then mounted in silicone 
molds before they were frozen in liquid nitrogen and stored at −80°C until sectioning. 12um 
wide sections were obtained, incubated in PBS for 30 minutes at 37°C to remove gelatin, 
and processed for imaging.
Western Blots
Stage HH4 gastrulating embryos co-electroporated with CAGG>nls-Cas9-nls and 
CAGG>H2B-RFP together with U6.3>Pax7.1.gRNAf+e (right) and U6.3>Control.gRNAf+e 
(left) were cultured ex ovo until stage HH9+, and the cranial region was dissected in 
Ringer’s. Dissected heads were split at the midline to collect both “Control” and 
“Treatment” halves, which were homogenized in 8M urea/2.5% Sodium Dodecyl Sulphate 
(SDS). 10μg of total protein from the control and treatment groups was run on a 4–12% 
polyacrylamide gel (ThermoFisher) and transferred to Nitrocellulose for 1h at 100V at 4°C 
(Amersham Protran Premium 0.2 NC). The membrane was incubated with primary 
antibodies against Pax7 (1:50), RFP (1:5000), Cas9 (1:5000), and FoxD3 (Santa Cruz; 
1:2000) diluted in 5% BSA/TBS-Tween in a sealed bag overnight at 4°C. The membranes 
were then incubated in secondary antibodies (KPL; α-Mouse 1:15,000; α-Rabbit 1: 30,000) 
dissolved in 5% milk/TBS-Tween. The Amersham ECL chemiluminescence reagents were 
used to develop signal, which was then visualized and captured by X-ray autoradiography. 
Quantification of the films was performed using FIJI (Schindelin et al., 2012).
Cell culture, transfection, and genotyping
Immortalized chicken DF-1 fibroblast cells (ATCC CRL-12203) were cultured at 37°C in 
5% CO2 in DMEM (Corning) supplemented with 10% fetal bovine serum (Gibco) and 
penicillin/streptomycin (Corning). To generate the Cas9-DF1 cell line, Cas9-2A-PuroR was 
cloned into pT2K-CAGGS (Sato et al., 2007) using Gibson Assembly (NEB). Cells were 
transfected in 12-well plates at approximately 80% confluency using Lipofectamine 3000 
(Invitrogen). Briefly, each well received 2μL of Lipofectamine 3000 reagent, 0.5μg of T2K-
CAGG>Cas9-2A-PuroR, and 0.5μg of CAGG>T2TP (Sato et al., 2007), and 2 μL P3000 
reagent following the manufacturer’s instructions. Transfected cells were incubated for 48 
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hours before the media was changed. At this point, the first round of selection was 
performed by treating the transfected cells with 4μg/mL puromycin (Alfa Aesar) for 6 days, 
making sure that the media was changed every 48 hours. Selected cells were then passaged 
twice in 8 days in media containing 4μg/mL puromycin to ensure propagation of a pure 
population of Cas9-integrated DF – 1 cells. To test gRNAs, these cells were transfected with 
1μg of U6.3>Pax7.1.gRNAf+e or 1μg of U6.3>Sox10.1.gRNAf+e using Lipofectamine 3000 
as described above. To validate our transfection protocol, a separate well was transfected 
with 1μg of CAGG>H2B-RFP. Cells transfected with gRNA plasmids were then reincubated 
for 48 hours at which point they were washed with sterile PBS, then trypsinized and 
genomic DNA was harvested following the QIAGEN DNeasy Blood and Tissue kit 
instructions. Genotyping was performed as described above.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Optimized CRISPR/Cas9 system to target genes in early chick embryos is 
presented.
• Chick U6 promoter results in increased gRNA transcription compared to 
human U6.
• CRISPR-mediated knockouts perturb downstream neural crest GRN 
components.
• Cas9-integrated chicken fibroblast cell line allows for rapid screening of 
gRNAs.
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Figure 1. Optimizing individual CRISPR/Cas9 components for application in chick embryos
A. Schematic of the Cas9 construct used in this study. Cas9 flanked with two Nuclear 
Localization Signal (NLS) sequences was cloned under the regulation of the chicken beta 
actin promoter (CAGG). B–D. Gastrulating Hamburger Hamilton stage HH4 embryos co-
electroporated with CAGG>nls-Cas9-nls, U6.3>Control.gRNAf+e, and CAGG>H2B-RFP, 
cultured ex ovo until stage HH9, and immunostained for Cas9 demonstrate efficient nuclear 
localization of Cas9 protein. Dotted line represents the midline of the neural tube. E. Pax7.1 
protospacer was cloned into a modified “F+E” scaffold. “F” (flip) modification is marked in 
red, “E” (extension) modification is marked in blue. Watson-Crick base pairing between the 
protospacer (highlighted in orange) and the target DNA strand is also shown. F. Design for 
the U6 promoter optimization assay. Human and Chicken U6 promoters were tested for their 
ability to drive expression of a modified gRNA cassette in which the terminator domain was 
replaced with GFP (see Materials and Methods for details). Transcripts synthesized through 
RNA Polymerase III-mediated transcription included the entire GFP sequence, which was 
then used for qualitative (in situ hybridization) and quantitative (qRT-PCR) assessment of 
promoter efficacy. DIG – Digoxigenin. G–H. Right side of stage HH4 chicken embryos were 
electroporated with the construct described in F. The embryos were cultured ex ovo until 
stage HH9-10, after which they were fixed and processed for in situ hybridization against 
GFP. The signal obtained in embryos electroporated with the chicken U6 promoter construct 
(n=3) was stronger than in embryos electroporated with the human U6 promoter construct 
(n=3). Dotted line represents the midline of the embryo. I. qRT-PCR primers specific to GFP 
were used to quantify the difference between the human and chicken U6 promoter-driven 
expression levels. GFP levels were first normalized to housekeeping gene 18S rRNA, and 
then RFP, which was co-electroporated (CAGG>H2B-RFP) along with the construct 
descried in F to account for electroporation variability between embryos. We observed 
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nearly a 4-fold increase in the activity of the chicken U6 promoter relative to the human 
counterpart (n=3 for each group). Error bars represent standard error of the means.
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Figure 2. CRISPR/Cas9-mediated knockout of Pax7
A. (Top) The G. gallus Pax7 gene contains 12 exons (black solid boxes). (Bottom) 
Nucleotide sequence surrounding the splice junction of exon 2 with the Protospacer 
Adjacent Motif (PAM) marked in red, and the Pax7.1.gRNA protospacer sequence 
highlighted with a red bar. B. Genotyping of Pax7 knockout cells isolated from HH10 
chicken embryos following electroporation of Pax7-targeting CRISPR reagents identifies 
multiple mutations that would result in a splicing error or frame shift in the predicted 
protein. C. Stage HH4 embryos were electroporated with U6.3>Control.gRNAf+e and 
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U6.3>Pax7.1.gRNAf+e on the left and right side, respectively, along with CAGG>nls-Cas9-
nls and CAGG>H2B-RFP on both sides, then cultured ex ovo until stage HH10. Dotted line 
represents midline of the neural tube. D. CRISPR/Cas9-mediated knockout of Pax7 resulted 
in a dramatic decrease in Pax7 protein level as assessed by immunostaining (n=21/21). E. 
Overlay of RFP (red) and Pax7 (green) channels revealed that all RFP+ (solid arrowhead) 
cells were Pax7-, indicating that all transfected cells lost Pax7 protein. Conversely, 
untransfected cells (E′, E″) retained endogenous Pax7 expression (arrowhead), suggesting 
that the protein levels in transfected cells on the right side of the embryo were lost as a result 
of CRISPR/Cas9-mediated activity. F. Embryos were cultured until stage HH10 and 
immunostained for migratory neural crest expression of HNK1. HNK1 levels on the Pax7 
knockout side were considerably reduced compared to the internal control, consistent with 
the role of Pax7 upstream of migratory neural crest formation. G. Another stage HH4 
embryo unilaterally electroporated with U6.3>Pax7.1.gRNAf+e, CAGG>nls-Cas9-nls and 
CAGG>H2B-RFP on the right side was cultured ex ovo until stage HH9 and stained for RFP 
and Pax7. Nuclei were labeled using DAPI stain. Transverse sectioning through this embryo 
revealed a nearly complete loss of Pax7 expression in the neural tube (dotted line). The 
zoomed-in images of the dorsal neural tube show high transfection rate (RFP+ cells; G′), 
loss of Pax7 on the right side (Pax7− cells; G″), and unaffected nuclear morphology (DAPI+ 
nuclei, G‴).
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Figure 3. CRISPR/Cas9-mediated knockout of Sox10
A. (Top) Schematic of the G. gallus Sox10 gene contains 4 exons (black solid boxes). 
(Bottom) Nucleotide sequence surrounding the Sox10 start codon, with the PAM marked in 
red, and the Sox10.1.gRNA protospacer sequence highlighted with a red bar. B. Genotyping 
of Sox10 knockout cells isolated from HH10 chicken embryos following electroporation of 
Sox10-targeting CRISPR reagents identifies multiple mutations that would result in a 
splicing error or frame shift in the predicted protein. C. A cartoon model of a stage HH10 
chicken embryo with the Sox10- expressed migratory cranial and vagal neural crest 
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(highlighted in violet). Stage HH4 embryos were electroporated with U6.3>Control.gRNAf
+e and U6.3>Sox10.1.gRNAf+e on the left and right side, respectively, along with 
CAGG>nls-Cas9-nls and CAGG>H2B-RFP on both sides, then cultured ex ovo until stage 
HH9-10, after which they were processed for in situ hybridization against Sox10. D–E. 
Reduced Sox10 expression levels were observed at stage HH9 in the emigrating cranial 
neural crest cells (D) and at stage HH10 in the migratory cranial neural crest cells (E). E′. 
Expression of Sox10 (embryo described in E) was reduced in the vagal neural crest and in 
the otic placode. Notably, the right side shows a nearly complete loss of Sox10 expression in 
the neural crest. F. Another stage HH4 embryo electroporated with U6.3>Control.gRNAf+e 
and U6.3>Sox10.1.gRNAf+e on the left and right side, respectively, along with CAGG>nls-
Cas9-nls and CAGG>H2B-RFP on both sides, was cultured ex ovo until stage HH10, and 
then immunostained for Sox10 and RFP. The right side shows a nearly complete loss of 
Sox10 protein compared to the left side control (n=9/9), indicating that CRISPR/Cas9-
mediated mutations at the Sox10 locus affected both transcript and protein levels. F′. 
Expression of Sox10 is detected in RFP+ transfected neural crest cells on the control side, 
whereas the transfected cells on the right side are Sox10−.
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Figure 4. Application of CRISPR/Cas9 to study epistatic relationships
A. Gene regulatory network model derived from previously studies shows regulatory 
interactions between key neural crest transcription factors. B–E. Gastrulating embryos were 
electroporated with CAGG>nls-Cas9-nls, CAGG>H2B-RFP, U6.3>Control.gRNAf+e on the 
left and either U6.3>Pax7.1.gRNAf+e (B-E) or U6.3>Sox10.1gRNAf+e (F–I) on the right 
side, cultured until stage HH9-10, then processed for in situ hybridization for Pax7 (B, F), 
FoxD3 (C, G), Ets1 (D, H), and Sox10 (E, I). Pax7 loss resulted in reduced expression of 
Gandhi et al. Page 23
Dev Biol. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
each downstream target in the neural crest (B–E), while Sox10 loss had no effect on the 
expression of its upstream regulators (F–I).
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Figure 5. CRISPR/Cas9 allows investigation of direct gene regulatory interactions
A. Pax7 regulates the expression of FoxD3 by direct transcriptional input into the NC1 
enhancer. The expression pattern in cranial neural crest cells is reproduced by strong 
expression from the mutated FoxD3-NC1.1 enhancer. B–D. Stage HH4 embryos were co-
electroporated with U6.3>Control.gRNAf+e and U6.3>Pax7.1.gRNAf+e on the left and 
right side, respectively, along with CAGG>nls-Cas9-nls, FoxD3-NC1.1>GFP, and 
CAGG>H2B-RFP on both sides. Embryos were cultured ex ovo until stage HH9-9+, and 
reduced Pax7 level was verified using immunostaining (C). The FoxD3-NC1.1 enhancer 
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driven expression of eGFP was almost completely lost on the side that was electroporated 
with U6.3>Pax7.1.gRNAf+e (D, arrow), recapitulating the previously published epistatic 
relationship between Pax7 and FoxD3. E. Embryos electroporated with U6.3>Pax7.1.gRNAf
+e or U6.3>Control.gRNAf+e along with CAGG>nls-Cas9-nls were cultured until stage 
HH9+, after which they were dissected along the midline. Whole cell lysates were isolated 
from the two groups, and immunoblots were performed using antibodies against Pax7, 
FoxD3, and Cas9. F–G. Quantitative western blot analysis normalized to Cas9 demonstrates 
efficient reduction in Pax7 and FoxD3 protein levels following Pax7 knockout when 
compared to control reagents. Error bars represent standard error of the means (n=3 
technical replicates). H–J. To validate the specificity of our optimized CRISPR/Cas9 system, 
we overexpressed Pax7 using CAGG>Pax7CDS-IRES-H2B-RFP (H), and co-electroporated 
this construct with CAGG>nls-Cas9-nls, U6.3>Pax7.1.gRNAf+e, and FoxD3-NC1.1>GFP 
reporter on the right side of a stage HH4 embryo (I–J). The left side was electroporated with 
CAGG>nls-Cas9-nls, U6.3>Control.gRNAf+e, and FoxD3-NC1.1>GFP, along with a 
CAGG>H2B-RFP construct. Overexpression of Pax7 rescued the activity of the FoxD3-
NC1.1 enhancer (J), demonstrating the specificity of Pax7 knockout mediated by our 
optimized CRISPR/Cas9 system.
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Figure 6. Construction of a Cas9-DF1 fibroblast cell line to validate gRNAs
A. The strategy employed to stably integrate a Cas9-2A-PuroR in chicken DF-1 fibroblasts 
using a T2TP transposase to access gRNA efficacy for in vivo applications. Cells were 
transfected with the two constructs and grown for 48 hours before the first round of selection 
on puromycin. gRNA plasmids were transfected using a simple lipofectamine-based 
protocol. B–D. After puromycin selection, the cells were immunostained for Cas9 to 
validate its stable integration and constitutive expression in the cells. Overlay of Cas9 
(green) expression with DAPI (magenta) revealed its proper nuclear localization in the cell 
line. E–F. Genotyping of Cas9-DF1 cells following transfection with Pax7 (E) and Sox10 (F) 
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targeting gRNA plasmids identifies multiple mutations that would result in a splicing error 
or frame shift in the predicted protein in vivo.
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